Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHU A Coruña, Spain.
Curr Top Med Chem. 2013;13(6):732-42. doi: 10.2174/1568026611313060006.
Effective management of Rheumatoid Arthritis (RA) is being hampered by the difficulties for its early diagnosis and the heterogeneity of the disease. Although early intervention can result in disease remission, it requires early diagnosis, and current diagnostic tests are not sufficiently accurate or sensitive in the early stages of RA. Therefore, research efforts are increasingly focused on gaining knowledge about RA pathogenesis, and also on the discovery of novel biological markers that enable early diagnosis and stratification of the disease, and thus the implementation of targeted therapies. Ongoing research includes the emergence of novel approaches for the characterization of molecules that play a role in RA, such as genomic, proteomic and metabolomic technologies. These techniques, coupled with sophisticated statistical methods, permit the simultaneous analysis of multiple targets, and have become very powerful tools in RA research both for etiopathogenesis studies and biomarker discovery. It is believed that proteomics will soon provide a much-needed novel therapeutic approach to treating RA. This chapter will focus on the utility of Proteomics in RA research to enable a better understanding of the disease process, and to provide novel protein biomarkers useful for early diagnosis, prognosis and the application of tailored treatments.
类风湿关节炎(RA)的有效管理受到早期诊断困难和疾病异质性的阻碍。虽然早期干预可以导致疾病缓解,但需要早期诊断,而目前的诊断测试在 RA 的早期阶段不够准确或敏感。因此,研究工作越来越集中在获得有关 RA 发病机制的知识上,以及发现新的生物标志物,以实现早期诊断和疾病分层,从而实施靶向治疗。正在进行的研究包括出现新的方法来描述在 RA 中发挥作用的分子,如基因组、蛋白质组和代谢组学技术。这些技术与复杂的统计方法相结合,允许同时分析多个目标,并且在 RA 研究中已经成为非常强大的工具,无论是在发病机制研究还是生物标志物发现方面。人们相信蛋白质组学将很快为治疗 RA 提供一种急需的新的治疗方法。本章将重点介绍蛋白质组学在 RA 研究中的应用,以更好地理解疾病过程,并提供新的蛋白质生物标志物,用于早期诊断、预后和实施针对性治疗。